rabeprazole has been researched along with Breast Neoplasms in 2 studies
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Using dynamic models, we determined that proton pump inhibitors such as rabeprazole and omeprazole indeed have the potential to cause clinically significant drug-drug interactions with CDK inhibitors in the treatment of estrogen receptor (ER) positive and HER2-positive breast cancer." | 4.12 | Inhibition of Cytochrome P450 Enzyme and Drug-Drug Interaction Potential of Acid Reducing Agents Used in Management of CDK Inhibitors for Breast Cancer Chemotherapy. ( Birangal, S; Farooqui, J; Fatima, F; Jagadish, PC; Patil, PH; Pinjari, J; Rao, M; Rastogi, H; Sharma, T; Shenoy, GG, 2022) |
| "Among the 48 human ABC proteins, the breast cancer resistance protein (BCRP/ABCG2) has been described as a pivotal player in cancer resistance." | 2.82 | Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators. ( Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zattoni, IF | 1 |
| Delabio, LC | 1 |
| Dutra, JP | 1 |
| Kita, DH | 1 |
| Scheiffer, G | 1 |
| Hembecker, M | 1 |
| Pereira, GDS | 1 |
| Moure, VR | 1 |
| Valdameri, G | 1 |
| Patil, PH | 1 |
| Jagadish, PC | 1 |
| Fatima, F | 1 |
| Birangal, S | 1 |
| Shenoy, GG | 1 |
| Rao, M | 1 |
| Farooqui, J | 1 |
| Rastogi, H | 1 |
| Sharma, T | 1 |
| Pinjari, J | 1 |
1 review available for rabeprazole and Breast Neoplasms
| Article | Year |
|---|---|
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Dr | 2022 |
1 other study available for rabeprazole and Breast Neoplasms
| Article | Year |
|---|---|
Inhibition of Cytochrome P450 Enzyme and Drug-Drug Interaction Potential of Acid Reducing Agents Used in Management of CDK Inhibitors for Breast Cancer Chemotherapy.
Topics: Aryl Hydrocarbon Hydroxylases; Breast Neoplasms; Computer Simulation; Cytochrome P-450 CYP2C19; Cyto | 2022 |